2[1]Jaffe ES,Harris N L,Stein H,et al.World Health Organization Classification of Tumor:Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues.France:IARC Press,Lyon,2001,171
3[2]Harris NL,Jaffe ES,Stein H,et at.A revised EuropeanAmerican classification of lymphoid neoplasm:A proposal from the International Lymphoma Study Group.Blood,1994,84:1361
4[3]Katzenberger T,Lohr A,Schwarz S,et al.Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell.Blood,2003,101 (2):699
5[4]Gary-Gouy H,Harriague J,Bismuth G,et al.Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production.Blood,2002,100 (13):4537
6[5]Rosenwald A,Wright G,Chan WC,et al.The use of molecular profiling to redict survival after chemotherapy for diffuse large B-cell lymphoma.N Engl J Med,2002,346:1937
7[6]Shipp MA,Ross KN,Tamayo P,et al.Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.Nat Med,2002,8:68
8[7]Barrans SL,Carter I,Owen RG,et al.Germinal center phenotype and bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large B-celllymphoma.Blood,2002,99:1136
9[8]Colomo L,Lopez-Guillermo A,Perales M,et al.Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.Blood,2003,101:78
10[9]Linderoth J,Jerkeman M,Cavallin-Stahl E,et al.Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma:A Nordic Lymphoma Group Study.Clin Cancer Res,2003,9:722
